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Background. Nonalcoholic fatty liver disease is present in up to 85% of adipose patients and may proceed to nonalcoholic
steatohepatitis (NASH). With insulin resistance and obesity being the main risk factors for NASH, the eﬀect of isolated sleeve
gastrectomy (ISG) on these parameters was examined. Methods. 236 patients underwent ISG with intraoperative liver biopsy from
December 2002 to September 2009. Besides demographic data, pre-operative weight/BMI, HbA1c, AST, ALT, triglycerides, HDL
and LDL levels were determined. Results. A signiﬁcant correlation of NASH with higher HbA1c, AST and ALT and lower levels
for HDL was observed (P<. 05, <.0001, <.0001, <.01, resp.). Overall BMI decreased from 45.0 ± 6.8 to 29.7 ± 6.5 and 31.6 ±
4.4 kg/m2 at 1 and 3 years. An impaired weight loss was demonstrated for patients with NASH and patients with elevated HbA1c
(plateau 28.08 kg/m2 versus 29.79 kg/m2 and 32.30 kg/m2 versus 28.79 kg/m2, resp.). Regarding NASH, a signiﬁcant improvement
of AST, ALT, triglyceride and HDL levels was shown (P<. 0001 for all). A resolution of elevated HbA1c was observed in 21 of
23 patients. Summary. NASH patients showed a signiﬁcant loss of body weight and amelioration of NASH status. ISG can be
successfully performed in these patients and should be recommended for this subgroup.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) describes a wide
spectrum of liver pathologies from simple steatosis to
steatohepatitis (NASH) and cirrhosis [1]. NAFLD has a
prevalence of 10% to 24% in the general population. Its
prevalence in obese persons is between 50% and 85%, and
65–90% in those with Type 2 Diabetes mellitus (T2DM) [2].
ForpatientsdiagnosedwithNASH,15–20%maydevelop
cirrhosis [3]. Given the fact that patients with NASH can
enter a ﬁnal cirrhotic pathway, it is not surprising that
NASH appears to portend an increased risk of hepatocellular
carcinoma [4].
Liver function test (lft) abnormalities are common in
patients with NAFLD, with elevations in aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) usu-
ally no greater than four times the upper limit of normal
andavariableAST/ALTratio,althoughALTusuallypredom-
inates [5]. Several noninvasive models have been established
to diﬀerentiate steatosis from NASH. It is not clear to date
whether biopsy is needed for the diagnosis of NASH [6].
The pathophysiology of NASH is regarded as a con-
tinuous process with two major factors. The ﬁrst factor
is considered to be insulin resistance resulting in steatosis
by increased elaboration of free fatty acids (FFA) that
are absorbed by the liver. The second factor is a series
of complex interactions between hepatocytes, stellate cells,
adipose cells, Kupﬀer cells, inﬂammatory mediators, and
reactive oxygen species that result in inﬂammation (NASH)
orcirrhosis[7].Here,theadiposetissue,whosefunctiongoes
far beyond gathering energy supplies, seems to play a key
role, being an essential endocrine organ producing a num-
ber of proteins demonstrating auto- and paracrine eﬀects
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Unlike other chronic diseases such as T2DM, there are
no formal treatment algorithms for patients with NAFLD.
Currently, management of NAFLD consists of modifying the
underlying risk factors including medical therapy [9–14]. To
induce weight loss in NASH patients, bariatric surgery is
discussed as a potential alternative.
Sleeve gastrectomy was ﬁrst introduced by Hess and
Marceau as a restrictive component of biliopancreatic diver-
sion with duodenal switch; it was initially not intended as
a standard single procedure [15]. Reported weight loss after
isolated sleeve gastrectomy (ISG) is good and ranges from
33% to 83.3% of EWL at the 1-year followup [16, 17]. Today
sleeve gastrectomy is performed as a stand-alone procedure
with a low operative risk. The most common complication
is staple line insuﬃciency and staple line bleeding [18].
Although it is mainly a restrictive procedure, resolution of
T2DM occurs in 50% to over 94% of patients after ISG by
1-year followup [19, 20].
The impact of bariatric surgery on NASH has been
examined for several bariatric interventions such as gastric
bypass or duodenal switch operations. Based on the data
reportedforisolatedsleevegastrectomyregardingweightloss
andameliorationofT2DM,weexaminedtheeﬀectofISGon
NASH and NASH-related comorbidities using clinical and
biological data.
2.MaterialandMethods
2.1. Patients. A review of prospectively collected data was
conducted for 236 consecutive patients, undergoing ISG at
Polyclinique Priollet, Chˆ alons en Champagne, France from
December 2002 to September 2009. Laparoscopic Sleeve
Gastrectomy was performed as previously described using
a 36 French calibration tube. Methylene blue was injected
intraoperatively to check for leakage [21].
Data collected included demographic data, preoperative
weight/BMI, HbA1c levels, liver functions tests (AST and
ALT), and lipid proﬁling (triglycerides, HDL, and LDL).
Early followup examinations were conducted at 6 weeks and
6 months after ISG, the later followup time span was yearly.
All data were entered prospectively into a custom-designed
database. Approval for the surgery and prospective audit was
granted by the institution’s clinical board.
2.2.HistologicalAssessment. Liverbiopsywasconductedper-
cutaneously during ISG under laparoscopic guidance using a
14-gauge 200mm Tru Cut Biopsy needle (CareFusion). The
biopsies were taken from the central part of the left lobe of
liver. All liver biopsy specimens were stained with H&E, PAS,
Masson trichrome, Perls and Van Gieson. For the assessment
of liver histology, one pathologist and a second observer
evaluated all biopsies according to the semiquantitative
scoring system for NAFLD proposed by Brunt et al. [22].
2.3. Statistics. Statistical analysis was conducted using Prism
5 for Mac OS X (GraphPad Software, Inc.)
One and two-way ANOVA were used to compare and
evaluate biological data. Spearman’s correlation was applied
Table 1: Patient characteristics.
Variable
Number of patients 236
female % 87
Age at operation (years) 37.9 ± 10.0∗
Weight (kg) 119.5 ± 19.4∗
BMIkg/m2 45.0 ± 6.8∗
Liver biopsy
NASH 87
normal liver histology 35
mean degree of steatosis 33.6 ± 24.7∗
HbA1c > 6.5% 23
∗mean ± standard deviation.
to asses a correlation between two variables. A P-value < .05
was considered signiﬁcant.
3. Results
Isolated sleeve gastrectomy was performed in 236 patients
with a mean BMI of 45 ± 6.8kg/m2 (Table 1). In order
to assess liver histology, intraoperative liver biopsy was
accomplishedinallpatients.Fromthe223histologicsamples
that could be ﬁnally evaluated, diagnosis was as follows:
35 patients with normal liver, 77 with steatosis, 87 with
NASH, 18 with ﬁbrosis, 3 with cirrhosis, 2 with siderosis,
and one patient with chronic hepatitis (Table 1). Patient
followup was conducted up to 3 years with a median overall
followup of 12 months. Among the clinical and biological
data analysed, NASH was signiﬁcantly correlated with higher
HbA1c, AST, and ALT levels and lower levels for HDL
(Spearman’s correlation <.05, <.0001, <.0001, <.01, resp.).
Elevated ALT levels could only be detected in 2 of 33 patients
with normal liver histology, but in 33 of 65 patients with
NASH (Fisher’s exact test P<. 0001). Other biological data
weresimilarinbothgroups(Table 3).Interestingly,therewas
a signiﬁcant correlation between a progressing liver disease
from normal liver histology over steatosis to NASH and
rising HbA1c levels (Pearson’s correlation P<. 01).
Our main objective was to determine if NASH has an
impact on the primary outcome after ISG, and equally
important to analyze the eﬀect of ISG on NASH.
Overall, ISG led to substantial weight loss with a BMI
r e d u c t i o no f4 4 %w i t h i n1y e a r( Table 2). Comparing
patients with normal liver histology to patients diagnosed
with NASH, a signiﬁcant reduction of body weight was seen
in both groups with a marginally larger preoperative BMI in
NASH patients (44.2 ± 5.6kg/m2 versus 45.9 ± 8.3kg/m2;
NS). Nonlinear regression analysis suggested equal initial
weight loss in both groups with an impaired reduction
of BMI for NASH patients beginning after the 9-month
followup (plateau 28.08kg/m2 versus 29.79kg/m2, Figure 1).
Overall,patientswithnormalliverhistologypresentedwitha
signiﬁcantly better weight reduction (Two-way ANOVA P<
.05). Determining HbA1c levels, 23 patients were considered
diabetic prior to the operation. Histologic evaluation ofJournal of Obesity 3
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Figure 1: Course of BMI after ISG for patients with HbA1c ≥
6.5% versus patients with HbA1c < 6.5%. Nonlinear regression
95% CI plateau 31.12 to 33.49kg/m2 versus 28.31 to 29.26kg/m2,
respectively, two-way ANOVA P<. 0001.
this subgroup revealed only 2 patients with normal liver
histology, 4 with steatosis, 14 with NASH, 1 with cirrhosis, 1
withﬁbrosis,and1withchronichepatitis.Therewasahighly
signiﬁcant diﬀerence in weight reduction compared to non-
diabetic patients, (two-way ANOVA P<. 001). Nonlinear
regression analysis revealed a broader diﬀerence in plateau
level comparing NASH patients to patients with normal liver
histology (plateau for HbA1c > 6.5% 32.30kg/m2 versus
HbA1c ≤ 6.5% 28.79kg/m2, Figure 2).
Regarding biological data, ISG could signiﬁcantly
improve HbA1c levels in all patients (Kruskal-Wallis P<
.0001, Table 2). In the 23 patients diagnosed with diabetes
priortosleevegastrectomy,medianHbA1clevelsnormalized
within 12 months (HbA1c 7.1% versus 5.6%, resp.). A
signiﬁcant reduction of HbA1c levels could also be shown
for NASH patients (Kruskal-Wallis P<. 01). In patients who
presentedwithnormalliverhistology,sleevegastrectomyhad
noeﬀectonHbA1c;however,meanHbA1cwasnotabovethe
cutoﬀ level of 6.5% at any given time point (Table 3).
Regarding lipids, ISG had a signiﬁcant impact on triglyc-
eridelevels.Overallmeantriglyceridelevelscouldbereduced
by37.5%after1year(Table 2).InpatientswithNASH,initial
triglyceride levels were higher than in patients with normal
liver histology (1.8 ± 1.4mmol/L versus 1.4 ± 0.7mmol/L).
Although a signiﬁcant reduction of triglycerides was seen in
both groups, NASH had a signiﬁcantly impairing impact on
triglyceride levels (two-way ANOVA P<. 05, Table 3).
Overall, analysis of the remaining lipid proﬁle showed
no inﬂuence of ISG on cholesterol, HDL, or LDL levels
(Table 2). Subgroup analysis revealed no signiﬁcant impact
on either cholesterol or LDL levels. HDL levels again
remainedunchangedforpatientswithnormalliverhistology.
In contrast, NASH patients presented a signiﬁcant improve-
ment of HDL (Kruskal-Wallis P<. 0001, Table 3).
Transaminase levels were examined as a representative
test for liver function and liver injury. In preoperative data,
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Figure 2: Course of BMI after ISG for patients with normal
liver histology versus patients with NASH. Nonlinear regression
95% CI plateau 27.27 to 28.89kg/m2 versus 28.69 to 30.89kg/m2,
respectively, two-way ANOVA P<. 05.
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Figure 3: Course of AST levels over a 3-year followup. A signiﬁcant
reductionofASTlevelscouldbeshownforNASHpatients(ANOVA
P<. 01).
astrongcorrelationcouldbeseenbetweenhightransaminase
levels and histologically diagnosed NASH (Spearman’s cor-
relation P<. 0001 and <.0001 for ALT and AST, resp.). For
patients with NASH, transaminase levels could be reduced
by over 50% within 6 months, achieving similarity to the
levels of patients with normal histology. This eﬀect remained
stable throughout the followup period. For patients with
normalhistology,transaminaselevelswerelowandremained
unchanged after sleeve gastrectomy (Figure 3).
4. Discussion
Inthepresentstudy,wereportameanBMIlossof15.3kg/m2
and 13.4kg/m2 at 12 and 39 months after ISG. This goes4 Journal of Obesity
Table 2: Overall clinical and biological data at 1- and 3-year followup.
Variable Before surgery 1 year after surgery 3 years after surgery P value
BMI kg/m2 45.0 ± 6.8 29.7 ± 6.5 31.6 ± 4.4 <.0001
HbA1c % 5.8 ± 1.1 5.3 ± 0.5 5.4 ± 1.2 <.0001
AST level U/L 22.7 ± 11.9 18.14 ± 9.9 20.0 ± 10.8 <.0001
ALT level U/L 34.2 ± 21.2 19.8 ± 14.8 23.01 ± 17.2 <.0001
Triglyceride level mmol/L 1.6 ± 1.1 1.0 ± 0.4 1.0 ± 0.5 <.0001
Cholesterol level mmol/L 5.1 ± 1.1 5.1 ± 1.0 5.1 ± 1.3 NS
LDL level mmol/L 3.1 ± 0.8 3.1 ± 1.0 3.1 ± 1.6 NS
HDL level mmol/L 1.3 ± 0.5 1.26 ± 0.5 1.6 ± 0.4 <.0001
Figures presented as mean ± standard deviation; P value determined with Kruskal-Wallis test.
Table 3: Separate consideration of clinical and biological data at 1- and 3-year followup for patients with NASH and normal liver histology.
Variable Before surgery 1 year after surgery 3 years after surgery P value P diﬀerence
Normal liver NASH Normal liver NASH Normal liver NASH Normal liver NASH
BMI kg/m2 44.2 ± 5.6 45.9 ± 8.3 28.2 ± 4.9 30.8 ± 8.8 30.3 ± 5.6 30.8 ± 5.3 <.0001 <.0001 <.05
HbA1c % 5.4 ± 0.5 6.1 ± 1.4 5.2 ± 0.4 5.4 ± 0.4 4.9 ± 0.4 5.2 ± 0.5 NS <.01 <.001
AST level U/L 17.9 ± 4.8 27.9 ± 14.4 18 ± 11.2 19.2 ± 9.3 19.2 ± 11.0 17.2 ± 2.4 NS <.01 NS
ALT level U/L 23.9 ± 9.1 42.1 ± 25.3 25.8 ± 27.3 17.5 ± 7.3 22.0 ± 16.1 12.2 ± 1.9 NS <.0001 NS
Triglyceride level mmol/l 1.4 ± 0.7 1.8 ± 1.4 0.9 ± 0.3 1.0 ± 0.3 0.8 ± 0.3 0.9 ± 0.4 <.05 <.0001 <.05
Cholesterol level mmol/L 5.3 ± 0.8 5.0 ± 1.0 5.7 ± 1.5 5.0 ± 0.8 4.8 ± 1.1 5.2 ± 0.9 NS NS NS
LDL level mmol/L 3.3 ± 0.7 3.0 ± 0.8 3.6 ± 0.9 3.1 ± 0.8 2.7 ± 1.1 3.3 ± 0.7 NS NS NS
HDL level mmol/L 1.4 ± 0.4 1.2 ± 0.4 1.7 ± 0.7 1.5 ± 0.3 1.5 ± 0.5 1.5 ± 0.3 NS <.0001 NS
Figurespresentedasmean ±standarddeviation;separateP valuesforNASHandnormalliverhistologyweredeterminedwithKruskal-Wallistest,P diﬀerence
determined with two-way ANOVA.
along with data recently published on 200 patients with
isolated sleeve gastrectomy, reporting a weight loss from
45.5kg/m2 to 30.6kg/m2 and 31.7kg/m2 at 12 and 18
months, respectively, using a 48 Fr calibration tube [23]. A
Greek centre, at which a 38 Fr bougie was used, reported
a comparable weight loss from 45.3kg/m2 to 30.5kg/m2
for 246 patients undergoing ISG [24]. In a series of 163
patients undergoing ISG using a 36 French calibration tube,
weight loss from 45.9kg/m2 to 33.1kg/m2 and 31.6kg/m2
waspresentedat1-and2-yearfollowup.Bougiesizedoesnot
seem to have an impact on initial weight loss; however, sleeve
dilatation and a consequent regain of weight occur for larger
bougies [18, 25].
A diabetic metabolism with high insulin levels and thus
inadequateglucoseandlipidhomoeostasisisexpectedtolead
topoorweightlossafterobesity surgery.Thisissupportedby
evidence found by Caiazzo et al., who reported an impaired
weight loss for diabetic patients after laparoscopic gastric
banding (LAGB) at one-year followup [26]. Schauer et al.
showed a comparable eﬀect on EWL% after laparoscopic
gastric bypass (LGB) [27]. Similar ﬁndings are presented by
Mathurin et al., who reported a signiﬁcantly lower weight
loss for patients presenting with insulin resistance prior to
obesity surgery (laparoscopic gastric banding and bypass)
[28]. However, these ﬁndings remain controversial, as others
report no diﬀerence regarding weight loss in their subgroup
analysis [29].
Our data suggest a signiﬁcantly impaired weight loss for
patientswithelevatedHbA1clevelsatbaselinedespiteagood
resolution of HbA1c, suggesting elevated Hb1Ac level as a
predictor for poor weight loss. However, weight loss is still
highly signiﬁcant in this group.
Comparing weight loss of patients diagnosed with NASH
during the operation to patients with normal liver histology,
an impairment in loss of BMI is evident. This phenomenon
can partly be explained by the impaired weight loss of
diabetic patients; however, only 14 of 87 patients with
NASH showed an HbA1c above 6.5%. Certainly, changes in
adipokine proﬁling play a pivotal role in NASH pathology.
New studies simultaneously evaluating NASH and adipokine
proﬁling should further evaluate this context.
Dixon et al. examined the eﬀect of LAGB on the
histopathological features of NAFLD, performing two con-
secutive liver biopsies and determining plasma aminotrans-
ferase concentrations at a median followup time of 30
months. This group could show a signiﬁcant correlation of
aminotransferase concentrations and presence of NASH at
the ﬁrst and second biopsies. An aminotransferase decrease
of 38% could best and signiﬁcantly predict the change in
NASH status [30].
Ulitzky et al. identiﬁed diabetes, ALT, and triglyceride
levels as independent risk factors for NASH in multivariate
analysis [31]. In our cohort, we could show a strong
correlation of preoperatively determined ALT and HbA1c
levels with histologically conﬁrmed NASH. A limitation
of our study is the lack of a second liver biopsy, which
prevents clearly deﬁning the eﬀect of sleeve gastrectomy on
liver histology. In the NASH subgroup, however, we couldJournal of Obesity 5
show a signiﬁcant reduction of triglyceride, HbA1c, and ALT
levels,resultinginasigniﬁcantreductionofNASHincidence,
whenapplyingtheUlitzkymodel[32].Furthermore,patients
diagnosed with NASH presented with a 39% decrease in AST
level.
Lacking a distinct algorithm, NASH therapy is mainly
based on the reduction of underlying risk factors. With
obesity being the single most signiﬁcant risk factor, weight
loss surgery is widely discussed for the management of
NASH. A recently conducted Cochrane research concern-
ing this subject analyzed 21 independent studies. Among
the bariatric procedures used, the majority of the studies
were conducted with Roux-en-Y gastric bypass (13) and
adjustable gastric banding (6). Regarding histological out-
comes, eighteen studies reported a signiﬁcant improvement
in the degree of steatosis and eleven studies reported an
improvement in histological markers of inﬂammation. In
11 of 16 studies lfts improved in the course of followup,
aggravation couldnot be observed [33]. In concordance with
the data presented above, our data suggest amelioration of
NASH after ISG.
An amelioration of T2DM after ISG is currently under
intensive discussion. Abbatini et al. showed a 80.9% res-
olution of T2DM after ISG over a 3-year followup [34].
In a series of 39 consecutive patients with preoperatively
diagnosed T2DM undergoing ISG, Vidal et al. presented
a resolution of HbA1c levels below 6.5% in 94.6% at 1-
year followup. Furthermore, they could show a 50% to 80%
resolution of metabolic syndrome associated ﬁgures such as
triglyceride and HDL levels, suggesting ISG as a successful
strategy for the management of diﬀerent cardiovascular
risk components of the metabolic syndrome [20]. In our
subgroup analysis of patients with elevated HbA1c, the
median HbA1c level was within normal ranges for 87% of
patients at 1- and 3-year followup.
The mechanism of T2DM resolution after sleeve gas-
trectomy is widely discussed. Some believe that hormonal
regulation plays a key role [20, 34]. In this regard, Peterli
et al. measured higher GLP-1 levels following ISG [35]. This
stimulation may be caused by a progressed gastrointestinal
passage after sleeve gastrectomy. Comparison of small bowel
transit time from patients after ISG to controls showed a
signiﬁcant reduction in transit time from 298.1 ± 9.2 to
199 ± 65.7 minutes [36]. Also, an increase on PYY can be
seen after ISG with possible amelioration of glucose control
[37, 38].
Overall, ISG is a restrictive operation. Weight loss is
greatest in the ﬁrst months after operation, so it does not
seem surprising to see rapid amelioration of T2DM. In a
recent, study performing LSG in nonmorbidly obese T2DM
patients resulted in a resolution of T2DM in up to 50% 1
year after operation. The eﬀect is related more to a decrease
of insulin resistance because of calorie restriction and weight
loss rather than to an increase of insulin secretion [19].
Besides weight loss, the amelioration of T2DM most
likely seems to create the condition for resolution of NASH
after ISG. Mathurin et al. proposed that remaining insulin
resistance is the main risk factor for nonresolution of NASH
after obesity surgery [28]. Furthermore, insulin sensitisers
such as Pioglitazone and Rosiglitazone can be applied as
medical treatment for NASH [10, 11]. The GLP-1 agonist
Exenatide could be administered with success; however, data
are scarce [39, 40].
Changes in adipokine proﬁling add to this eﬀect, espe-
cially given the fact that only 14 of 87 patients with NASH
had HbA1c levels above 6.5%. For adiponectin, it was
demonstrated that lower adiponectin levels are associated
with increased severity of hepatic inﬂammation. A repletion
of adiponectin in mice resulted in signiﬁcant improvements
in steatosis and inﬂammation [41, 42]. For TNF-α elevated
plasma concentrations, as can be detected in obese patients,
mediated hepatic injury by inhibition of mitochondrial
electron transport and release of reactive oxygen species that
stimulate lipid peroxidation [43]. Clearly more research is
needed to further clarify these correlations.
5. Conclusion
ISG conducted in 236 patients resulted in a signiﬁcant and
sustainedweightlosscomparabletodatapresentedbyothers.
Although a signiﬁcant diﬀerence was seen between NASH
patients and patients with normal histology, NASH patients
showed a highly signiﬁcant loss of body weight. For this sub-
group, amelioration of HbA1c levels and equally important
amelioration of liver histology could be demonstrated. ISG
can be successfully performed in NASH patients and, as a
fairly easy and safe bariatric intervention to conduct, it can
be particularly recommended for this subgroup.
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